Burning Rock Biotech
Guangzhou
About Burning Rock Biotech
Burning Rock focuses on providing individualized cancer treatment guidance for the patients. Using medical and bio informatics plus Next-Generation Sequencing (NGS) as the core technologies, the company is committed to offering one-stop solution for clinical and R&D services concerning the genetic testing of individualized cancer treatment. Established in March 2014, Burning Rock is headquartered in Beijing. Its first medical laboratory, "Guangzhou Burning Rock Medical Examination Institute Co., Ltd." is situated on Guangzhou International Bio Island which is blessed with a picturesque environment and rich in scientific research deposits. Later it established a R&D center in Shanghai. It occupies over 10,000 ㎡ in total. Burning Rock is committed to guiding the individualistic treatment of tumor patients, centered around NGS and biomedical informatics, with conventional tumor molecular pathology detection as the cornerstone, trying to build one-stop solutions for individualistic treatment clinical detection service and scientific research of tumor.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $50K – $100K
- Total funding: $193.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2022)
- Ticker: nasdaq:BNR
- Website: brbiotech.com?english.html
- Phone: 020-34037872
Industries & Categories
Biotechnology, Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/burning-rock-biotech-141646 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.